Publications by authors named "J Lakey"
Pancreatic islet transplantation is proposed as a cure for type 1 diabetes mellitus (T1D). Despite its success in optimal regulation of glucose levels, limitations in longevity of islet grafts still require innovative solutions. Inflammatory stress post-transplantation and loss of extracellular matrix attribute to the limited β-cell survival.
View Article and Find Full Text PDFArticle Synopsis
- Islet transplantation is a promising alternative to whole pancreas transplantation for type 1 diabetes patients facing severe hypoglycemia, but challenges remain regarding cost-effectiveness and donor sensitization.
- This pilot study utilized advanced nuclear magnetic resonance spectroscopy to examine human pancreatic tissue before and after cold-storage, revealing signs of hypoxia and subsequent recovery of islet viability post-incubation.
- A correlation was found between specific metabolic changes in the pancreatic tissue and the responsiveness of the isolated islets, indicating that assessing these features could help identify suitable pancreases and enhance transplantation outcomes.
Background: The global incidence of type 2 diabetes (T2D) persists at epidemic proportions. Early diagnosis and/or preventive efforts are critical to attenuate the multi-systemic clinical manifestation and consequent healthcare burden. Despite enormous strides in the understanding of pathophysiology and on-going therapeutic development, effectiveness and access are persistent limitations.
View Article and Find Full Text PDFThe scourge of type-1 diabetes (T1D) is the morbidity and mortality it and its complications cause at a younger age. This propels the constant search for better diagnostic, treatment, and management strategies, with the ultimate quest being a cure for T1D. Recently, the therapeutic potential of exosomes has generated a lot of interest.
View Article and Find Full Text PDFArticle Synopsis
- Insulin is released in rhythmic pulses from pancreatic beta-cells to regulate blood glucose levels, but in type 2 diabetes, this process becomes irregular, especially in certain populations such as American Indians and Native Alaskans who show decreased beta-cell function and higher diabetes rates.
- A study reviewed metabolic outcomes in 10 Native Americans after six months of intravenous hormone therapy, reporting significant reductions in markers like hemoglobin A1C and fasting glucose levels.
- The findings suggest that physiologic hormone administration could potentially improve metabolic syndrome metrics, indicating a need for further research through randomized controlled trials.